1月5日，脑机接口板块领涨A股。截至发稿，板块涨幅超13%，个股方面，倍益康30CM涨停，三博脑 科、博拓生物、美好医疗、翔宇医疗等近20股涨停。 消息面上，马斯克日前在社交媒体上表示，其脑机接口公司Neuralink将于2026年开始对脑机接口设备 进行"大规模生产"，并转向"更加精简和几乎完全自动化的外科手术流程"。其最新技术的设备电极丝可 直接穿过硬脑膜，而无需将其切开。 据悉，Neuralink的产品重点仍集中在治疗神经系统疾病，包括瘫痪、肌萎缩、帕金森、老年痴呆和视力 障碍。 同时，国内医疗企业在该领域不断实现技术突破。三博脑科旗下的福建三博已帮助受试者偏瘫上肢恢复 自由抓握功能；"北脑二号"也有望在2026年进入临床验证。博拓生物参股公司的植入式脑深部神经刺激 系统已进入科研性临床，产品拟2026年末启动注册。 不仅如此，资本市场对该领域的投资也较为火热，据动脉橙数据库不完全统计，2025年1—11月，我国 脑机接口领域共完成24起融资，同比增长30%。 中信建投在研报中分析称，脑机接口是医疗投资也是科技投资，短期来看主要应用于疾病治疗，长期来 看若能实现增强人、并与AI和机器人融合，有望打开万亿 ...

Group 1: Quantum Technology - The "quantum + supercomputing" integration innovation platform has been established in Chengdu, deploying China's first 550-qubit coherent optical quantum computer, enabling the collaboration of classical high-performance computing and quantum computing [7][8] - The deployment of the 550-qubit quantum computer fills the gap in the central and western regions of China for quantum computing capabilities, establishing a complementary regional computing power structure with eastern regions [8][9] Group 2: Biological Manufacturing - The first sugar science key laboratory in Beijing has been approved, co-established by Huaxi Biological and Peking University, focusing on precise manufacturing and functional applications of sugars [10][11] - Huaxi Biological aims to leverage this laboratory to enhance its capabilities in synthetic biology, expanding from hyaluronic acid production to comprehensive sugar biological research [11] Group 3: Hydrogen Energy and Nuclear Fusion - The world's first 30 MW pure hydrogen gas turbine has achieved stable operation, marking a significant step in hydrogen energy transitioning from a "power consumer" to a "grid regulator" [12][13] - The EAST nuclear fusion device has confirmed the existence of a density-free regime, providing critical physical evidence for efficient operation of fusion reactors [18][19] - The Chinese Academy of Sciences has completed the manufacturing of all ITER correction coil procurement packages, marking a significant achievement in domestic R&D capabilities for nuclear fusion components [22] Group 4: Brain-Computer Interface - Neuralink plans to begin mass production of brain-computer interface devices in 2026, aiming to automate surgical procedures and enhance device performance [23][24] - The "Beijing Brain No. 1" system has been implanted in five spinal cord injury patients, achieving clinical breakthroughs, with plans for clinical trials to start in mid-2026 [26][27] - The "Guangdong-Hong Kong-Macao Greater Bay Area Brain Science and Central Nervous System Disease AI Innovation Alliance" has been launched, focusing on research and development in brain science and related technologies [28] Group 5: Embodied Intelligence - Woan Robotics has gone public in Hong Kong, focusing on household scenarios with plans to launch a humanoid household robot in January 2026 [29][30] - The "Qiyuan Q1," the world's first small-sized humanoid robot with full-body force control, has been released, targeting research and interactive applications [33][34] Group 6: Future Industry Catalysts - A table has been organized detailing key catalytic events for six future industries in 2026, including important conferences and technological milestones [36][38]

Group 1 - The brain-computer interface (BCI) sector is experiencing significant growth, with companies like Neuralink and Merge Labs leading the charge in invasive and non-invasive technologies respectively [1][2] - Neuralink plans to begin large-scale production of its BCI devices in 2026, introducing a streamlined and automated surgical process that avoids traditional invasive methods [1] - Zhejiang Qiangnao Technology Co., Ltd. is emerging as a domestic unicorn in the BCI field, focusing on non-invasive technology and aiming for an IPO in mainland China or Hong Kong by 2026 [2] Group 2 - Qiangnao Technology has formed a strategic partnership with Lingyi iTech, enhancing both companies' market competitiveness and technological capabilities in the BCI and robotics sectors [2] - The global BCI market is projected to grow to approximately $12.4 billion by 2034, with a compound annual growth rate (CAGR) of 17% from 2025 to 2034, driven by technological advancements and policy support [2]

Core Viewpoint - The A-share market experienced a significant upward movement on the first trading day of 2026, with the Shanghai Composite Index rising over 1% and surpassing the 4000-point mark, driven by a surge in brain-computer interface (BCI) stocks [1] Group 1: Market Performance - The combined trading volume of the Shanghai and Shenzhen markets exceeded 1.6 trillion yuan, indicating a notable increase in market activity [1] - Several BCI-related stocks, including Sanbo Brain Science, Aipeng Medical, and others, reached the daily limit of a 20% increase [1][2] Group 2: Industry Insights - Elon Musk's recent comments regarding Neuralink's plans to mass-produce BCI devices by 2026 have sparked interest in the BCI sector, with expectations of significant advancements in technology and applications [3] - The global BCI market is projected to grow from $2.94 billion in 2025 to $12.4 billion by 2034, with a compound annual growth rate (CAGR) of 17% from 2025 to 2034 [3] - Recent research breakthroughs in medical applications such as movement recovery and communication have been reported, supported by favorable policies from the government, including separate pricing for new BCI technologies [4]

Core Viewpoint - The brain-computer interface (BCI) concept stocks surged on the first trading day of 2026 in the A-share market, driven by significant developments in the industry, including Neuralink's plans for mass production of BCI devices and supportive policies for high-end medical devices [1][3]. Group 1: Stock Performance - Multiple BCI-related stocks, including Aipeng Medical, Xiangyu Medical, and Meihua Medical, reached their daily limit up, with Aipeng Medical rising by 20% to 33.30 CNY [2][1]. - Other notable performers included Sainuo Medical and Hanwei Technology, which saw increases of 17.31% and 15.99%, respectively [2][1]. - The overall trend in the Hong Kong market mirrored that of the A-share market, with stocks like Nanjing Panda Electronics rising over 30% [2][1]. Group 2: Industry Developments - Elon Musk's Neuralink announced plans to begin large-scale production of BCI devices in 2026, signaling a significant advancement in the field [3]. - The integration of artificial intelligence in healthcare is accelerating, with 207 AI medical devices expected to be approved by 2025, highlighting the rapid technological progress [3]. - The global BCI market is projected to reach $12.4 billion by 2034, with a compound annual growth rate (CAGR) of 17% from 2025 to 2034, indicating substantial growth potential [3]. - Recent policy support, including the inclusion of implantable BCI devices in a priority approval list by the National Medical Products Administration, is expected to further enhance the commercialization process [3].

Core Viewpoint - The A-share market experienced a strong start to 2026, with major indices showing significant gains and a notable increase in trading volume, indicating a shift in market sentiment towards optimism [1] Market Performance - The Shanghai Composite Index rose by 1.07%, reclaiming the 4000-point mark, which is a key technical breakthrough and a sign of improved market confidence [1] - The Shenzhen Component Index and the ChiNext Index increased by 1.87% and 2.15%, respectively, while the STAR 50 Index surged by 4.05%, highlighting strong investor interest in technology innovation [1] - The total trading volume reached 1.65 trillion yuan, an increase of over 320 billion yuan compared to the previous trading day, indicating a robust volume-price relationship essential for sustaining the rebound [1] Sector Highlights - The brain-computer interface sector was the most prominent, driven by Elon Musk's announcement regarding Neuralink's plans for large-scale production of brain-computer interface devices in 2026, marking a significant step towards commercial application [2] - The innovative drug sector also performed strongly, supported by data from the National Medical Products Administration indicating that 76 innovative drugs are expected to be approved in 2025, a historical high, with total licensing transactions exceeding $130 billion [2] - The insurance sector saw leading companies' stock prices surge to historical highs, driven by a 7.6% year-on-year increase in premium income for the insurance industry in the first 11 months of 2025, with life insurance growth reaching 9.1% [2] Additional Sector Insights - The commercial aerospace sector continued its strong performance due to favorable policies related to the national Beidou application network [3] - The storage chip sector experienced a collective surge based on expectations of a cyclical turnaround, with DRAM contract prices anticipated to rise significantly [3] - Some sectors, such as the Hainan Free Trade Zone and stablecoin concepts, faced adjustments, reflecting a dynamic shift of funds from old themes to new mainlines [3] Market Outlook - The strong trading volume and upward movement of indices lay a solid foundation for a potential "spring market," with a clear focus on "hard technology" and "new growth" sectors [3] - Key sectors to watch include brain-computer interfaces, commercial aerospace, innovative drugs, and semiconductors, which are expected to maintain high activity levels due to both long-term growth potential and short-term policy catalysts [3] - Investors are advised to focus on technology growth leaders with matching performance and valuation, and to monitor whether trading volume can remain at elevated levels, which is crucial for assessing the strength and sustainability of the market [3]

Market Performance - The A-share market opened strongly on January 5, with the Shanghai Composite Index returning to the 4000-point mark after 34 trading days, closing up 1.07% [2][3] - The Shenzhen Component Index rose by 1.87%, and the ChiNext Index increased by 2.15% [2] - Over 4000 stocks in the market rose, with 98 stocks hitting the daily limit [2] Sector Performance - The brain-computer interface (BCI) sector saw a significant surge, with a half-day increase of 13.06%, leading the market [11] - Other sectors that performed well included medical devices, hyperbaric oxygen chambers, and insurance [11][12] - The A500 ETF saw a trading volume exceeding 110 billion yuan, indicating strong institutional interest [9] Investment Trends - Institutional funds have shown significant net inflows into stock ETFs since December, particularly into A500-related ETFs, indicating a bullish sentiment for the upcoming spring market [9] - The stability of the RMB exchange rate has attracted foreign capital back to A-shares and Hong Kong stocks, suggesting a new round of asset revaluation [9] - The ETF market, valued at 6 trillion yuan, is drawing increasing competition from various institutions, which may lead to product innovation and market development [9] Brain-Computer Interface Sector - The BCI sector is experiencing a pivotal moment with multiple catalysts, including Elon Musk's announcement of large-scale production of BCI devices by Neuralink in 2026 [14] - Domestic policies are increasingly supportive, with the National Medical Products Administration accelerating the review process for BCI medical devices [15] - The BCI market is expected to expand significantly due to ongoing technological advancements and supportive government policies, with a focus on clinical applications and consumer scenarios [15]

据新华社旧金山电，埃隆·马斯克2025年12月31日通过社交平台发布重磅消息，旗下脑机接口公司 Neuralink计划于2026年启动脑机接口设备大规模量产，并同步推出全自动化外科手术流程。这一规划标 志着脑机接口技术从临床验证阶段向产业化落地迈出关键一步，也成为A股人脑工程板块的强力催化， 截至1月5日上午收盘，该板块指数大涨12.56%至6245.59点，超十只概念股收获"20CM"涨停。 据Neuralink官网及马斯克公开发言内容，截至2025年9月份，该公司已完成12例脑机接口设备人体植入 手术，临床试验参与者累计使用设备时长超1.5万小时，患者可通过意念实现光标操控、文字输入甚至 机械臂辅助进食等操作，设备实际运行稳定性达标率超98%。同时，第二代手术机器人实现技术升级， 将单根电极植入时间从17秒压缩至1.5秒，整体手术时长从6小时缩短至20分钟内；成本端也实现大幅下 降，单台设备植入成本从早期百万美元级降至10万美元以内，全自动化手术落地后有望进一步下探至5 万美元区间。 《证券日报》记者注意到，A股相关上市公司早已在脑机接口赛道展开布局，从设备研发到临床应用多 维度切入，试图抢占行业发展先机 ...

Core Insights - The market sentiment is positive, with the Shanghai Composite Index returning to 4000 points and strong performance in the Sci-Tech Innovation Board related indices [1] - The brain-computer interface (BCI) sector is experiencing a collective surge, with multiple stocks hitting the daily limit [1] - Elon Musk announced on social media that Neuralink's BCI products will enter mass production by January 1, 2026, with nearly automated surgical operations and enhanced safety features [1] Industry Developments - The first fully implanted, wireless, and fully functional BCI product developed by Brain Tiger Technology has achieved its first clinical implantation at Huashan Hospital affiliated with Fudan University [2] - On November 13, Ladder Medical announced that its self-developed "implantable wireless BCI system" entered the special review process of the National Medical Products Administration, becoming the first invasive BCI product to enter this "green channel" [2] - The 2025 BCI Conference showcased clinical progress of the NEO BCI system by Borui Kang, with 32 patients undergoing implantation across 11 hospitals, showing no adverse reactions and significant improvement in hand function [2] Technological Advancements - BCI technology is undergoing rapid iteration and upgrade, with breakthroughs in non-invasive devices improving signal quality and portability [3] - In the invasive field, the development of flexible electrodes is expected to enhance system safety, comfort, and long-term stability [3] - Multimodal integration of electromyography and electroencephalography signals is becoming a key trend for improving overall stability and reliability [3] Market Performance - As of January 5, the Sci-Tech Biomedicine ETF (588250.SH) rose by 4.93%, with its related index increasing by 5.01% [3] - Notable component stocks include BeiGene (up 11.46%), United Imaging (up 4.36%), and Eifang Bio (up 9.21%) [3] - Southwest Securities suggests focusing on three directions: overseas expansion, BCI, and AI healthcare, indicating that the 2026 market will revolve around R&D progress, commercialization, and internationalization [3]

Market Overview - The A-share market saw a strong opening on January 5, with the Shanghai Composite Index returning to 4000 points, closing at 4011.45, up 1.07% [1] - The Shenzhen Component Index rose by 1.87%, and the ChiNext Index increased by 2.15% [1] Trading Volume - The total trading volume in the Shanghai and Shenzhen markets reached 1.64 trillion yuan, an increase of 323.8 billion yuan compared to the previous trading day [3] Stock Performance - A total of 4064 stocks rose, with 99 stocks hitting the daily limit, while 1236 stocks declined [3] - The sectors that performed well included insurance, medical devices, semiconductors, and gaming, with brain-computer interface concept stocks experiencing significant gains [3] Sector Highlights Brain-Computer Interface - Brain-computer interface stocks surged, with several companies hitting the daily limit [6] - Notable performers included Xiangyu Medical, Guanhao Biological, Meihua Medical, Aipeng Medical, and Lepu Medical, all recording a 20% increase [6][7] - Elon Musk's Neuralink announced plans for large-scale production of brain-computer interface devices by December 31, 2026, which is expected to revolutionize the field by reducing invasiveness [9] Semiconductor Sector - The semiconductor sector also showed strength, with multiple stocks reaching their daily limit [10] - Key performers included Dongwei Semiconductor and *ST Tianlong, both achieving a 20% increase [11] - TSMC announced it received U.S. government approval to import chip manufacturing equipment to its Nanjing facility in 2026, which is a positive development for the sector [12] Insurance Sector - The insurance sector experienced a rally, with significant gains from major companies [13] - Xinhua Insurance rose by 7.53%, China Pacific Insurance by 6.16%, and China Life Insurance by over 5% [13][14] - The insurance industry reported a total premium income of 57.629 billion yuan for the first 11 months of 2025, a year-on-year increase of 7.6% [14]